Article

Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia.

Department of Medicine, Leukemia Section, Clinical Cytogenetics Laboratory, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Blood (Impact Factor: 10.43). 01/2002; 98(12):3492-4.
Source: PubMed

ABSTRACT Acute monoblastic leukemia (acute myeloid leukemia [AML], French-American-British type M5a) with leukemia cutis developed in a patient 6 weeks after the initiation of erythropoietin (EPO) therapy for refractory anemia with ringed sideroblasts. AML disappeared from both marrow and skin after the discontinuation of EPO. Multiparameter flow cytometric analysis of bone marrow cells demonstrated coexpression of the EPO receptor with CD45 and CD13 on the surface of blasts. The incubation of marrow cells with EPO, compared to without, resulted in 1.3- and 1.6-fold increases, respectively, in tritiated thymidine incorporation and bromodeoxyuridine incorporation into CD13(+) cells. Clinical and laboratory findings were consistent with the EPO-dependent transformation of myelodysplastic syndrome (MDS) to AML. It is concluded that leukemic transformation in patients with MDS treated with EPO may be EPO-dependent and that management should consist of the discontinuation of EPO followed by observation, if clinically feasible.

Download full-text

Full-text

Available from: Hilal Arnouk, Aug 21, 2015
1 Follower
 · 
92 Views
  • Source
    • "Evidence that a trophic factor can produce malignancy by stimulation of malignant stem cells is the occurrence of a clinically significant cancer that did not exist until a trophic factor was given, that regressed when the factor was withdrawn, and that demonstrated trophicfactor dependent growth in vitro. This was indeed true for a patient with epogen-driven acute myelogenous leukemia (Bunworasate et al., 2001), but to the best of our knowledge, this is the only case history where the cause and effect relationship between trophic factor and stimulation of malignant cells is so iron clad. Epogen is a synthetic form of erythropoietin, a polypeptide hormone produced mainly in the kidneys which stimulates production of red blood cells from erythroblast precursors in the bone marrow. "
    Cancer Stem Cells - The Cutting Edge, 08/2011; , ISBN: 978-953-307-580-8
  • Source
    • "The negative effect of Epo on tumour growth may be further aggravated by its angiogenic activity. Epo administration to patients with multiple myeloma or with myelodysplastic syndrome might promote an angiogenic response in their bone marrow and cause further malignant transformation, resulting in plasma cell leukaemia and acute monoblastic leukaemia, respectively [60] [61] [62]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This editorial is focused on the double controversial action of erythropoietin, acting as anticancer agent and as a promoting cancer agent.
    Leukemia Research 08/2008; 33(1):1-4. DOI:10.1016/j.leukres.2008.06.004 · 2.69 Impact Factor
  • Source
    • "Secondly, the possibility to induce, in low-risk MDS patients with karyotypic aberrations, the in vivo expansion of cytogenetically normal bone marrow erythroid and myeloid precursors suggests that, in some patients, the administration of recombinant growth factors acting on the stem cell compartment could represent a therapeutic strategy to improve the quality of bone marrow harvest for transplantation procedures, as recently described (Pierelli et al, 1999). In this perspective, however, we need a better understanding of the physiological mechanisms underlying this phenomenon and a precise identification of the patients who could benefit from this procedure to avoid the expansion of abnormal clones and therefore disease progression (Bunworasate et al, 2001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The issue of whether, in patients affected by myelodysplastic syndromes (MDS), haematological response to cytokines, particularly to recombinant human erythropoietin (rHuEpo), is a phenomenon related to the stimulation of normal haemopoietic cells or to the differentiation of cells belonging to the abnormal clone remains an open question. To assess the pattern of response to rHuEpo treatment of bone marrow (BM) cells, we evaluated in 13 low-risk MDS patients with known cytogenetic abnormalities the number of cytogenetically normal and abnormal cells by conventional cytogenetic analysis (CCA) and by a fluorescence in situ hybridization (FISH) technique, enabling the simultaneous visualization of FISH chromosomal abnormalities in morphologically and immunophenotypically identifiable BM elements. Patients responding to rHuEpo presented a lower number of abnormal metaphases at diagnosis in comparison with patients who did not respond (22.74% vs 76.23%, P = < 0.001). This was confirmed by the combined morphological FISH analysis, showing that, before treatment, BM samples from patients responding to rHuEpo had a lower proportion of both FISH abnormal erythroid (36.48% vs 66.93%, P = 0.002) and myeloid (40.76% vs 67.70%, P = 0.014) elements than unresponsive patients. After rHuEpo treatment, responding patients presented a significantly lower proportion of FISH abnormal erythroid precursors than observed before treatment (16.93%vs 36.48%, P = 0.017). Likewise, in responding patients, a significantly lower proportion of FISH abnormal erythroid elements (16.93% vs 66.30%, P < 0.001) was detected in comparison with unresponsive patients. These findings provide evidence that, in low-risk MDS patients with known cytogenetic abnormalities, response to rHuEpo may be due to the proliferation of karyotypically normal erythroid precursors, possibly representing residual normal erythroid elements.
    British Journal of Haematology 12/2002; 119(3):652-9. DOI:10.1046/j.1365-2141.2002.03867.x · 4.96 Impact Factor
Show more